AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23811853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 15 mg/day
Number of subjects: 29
Study 23811853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 29
Study 21457428 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (10, 30, 100, 200, 400, 600 or 800 mg q.d. or 400 mg b.i.d.)
Number of subjects: 63
Study 21457428 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (doses >200 mg before breakfast)
Number of subjects: 63
Study 21457428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17057562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg + Ketorolac 60 mg
Number of subjects: 80
Study 17057562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg
Number of subjects: 80
Study 17057562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 80
Study 17057562 — intervention group
Group type: COMPARATOR
Intervention: Control group (C): IM chorpheniramine 20 mg + IV normal saline
Number of subjects: 80
Study 15064540 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval debulking surgery
Number of subjects: 0
Study 15064540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by interval debulking surgery
Number of subjects: 0
Study 15064540 — intervention group
Group type: COMPARATOR
Intervention: Second-look operation
Number of subjects: 0
Study 11694377 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-man FNAB technique
Number of subjects: 44
Study 11694377 — intervention group
Group type: COMPARATOR
Intervention: Standard FNAB technique
Number of subjects: 44
Study 9400786 — intervention group
Group type: EXPERIMENTAL
Intervention: MSL-109, 60 mg intravenously every 2 weeks
Number of subjects: 209
Study 9400786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 9400786 — intervention group
Group type: EXPERIMENTAL
Intervention: MSL-109, 60 mg intravenously every 2 weeks (relapsed retinitis)
Number of subjects: 209
Study 9400786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (relapsed retinitis)
Number of subjects: 209
Study 9400786 — intervention group
Group type: EXPERIMENTAL
Intervention: MSL-109, 60 mg intravenously every 2 weeks (newly diagnosed retinitis)
Number of subjects: 209
Study 9400786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (newly diagnosed retinitis)
Number of subjects: 209
Study 8265305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of human serum immunoglobulin (300 mg/kg body weight)
Number of subjects: 98
Study 8265305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 98
Study 3687522 — intervention group
Group type: EXPERIMENTAL
Intervention: Real smoking
Number of subjects: 12
Study 3687522 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 12
Study 28255655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL of 1% HA (H-HA)
Number of subjects: 168
Study 28255655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mL of 1% HA (L-HA)
Number of subjects: 168
Study 28255655 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mL of 0.01% HA (control group)
Number of subjects: 168
Study 27464313 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation Training (ART)
Number of subjects: 201
Study 27464313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 201
Study 27464313 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 201
Study 24632760 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy for primary care (PST-PC)
Number of subjects: 247
Study 24632760 — intervention group
Group type: COMPARATOR
Intervention: Dietary coaching
Number of subjects: 247
Study 24632760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PST-PC and dietary coaching
Number of subjects: 247
Study 22686556 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual supervision
Number of subjects: 42
Study 22686556 — intervention group
Group type: EXPERIMENTAL
Intervention: Group supervision
Number of subjects: 42
Study 22686556 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no supervision)
Number of subjects: 42
Study 20837300 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate whole body hypothermia
Number of subjects: 0
Study 20837300 — intervention group
Group type: COMPARATOR
Intervention: Standard care on normothermia
Number of subjects: 0
Study 19083441 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (vitamin C 1000 mg and vitamin E 800 IU)
Number of subjects: 16
Study 19083441 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 16
Study 19083441 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study 11755291 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and support intervention
Number of subjects: 88
Study 11755291 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 9881881 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (20 mg/d)
Number of subjects: 343
Study 9881881 — intervention group
Group type: COMPARATOR
Intervention: No beta-carotene supplementation (Control)
Number of subjects: 343
Study 8061849 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril treatment (initial dose 6 or 12 mg once daily, titrated to 3-24 mg)
Number of subjects: 11
Study 8061849 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril treatment
Number of subjects: 11
Study 2647122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 24
Study 2647122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 4904222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar and hypoosmolar solutions
Number of subjects: 0
Study 4904222 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 4904222 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal ulcer patients
Number of subjects: 0
Study 31158425 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills intervention (SSI) for 10 weeks
Number of subjects: 53
Study 27856269 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintain antimicrobials
Number of subjects: 176
Study 27856269 — intervention group
Group type: COMPARATOR
Intervention: Withdraw antimicrobials
Number of subjects: 176
Study 26132535 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans with children in the home
Number of subjects: 94
Study 26132535 — intervention group
Group type: EXPERIMENTAL
Intervention: Having children in the home
Number of subjects: 94
Study 23048188 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 478
Study 23048188 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 478
Study 21321036 — intervention group
Group type: EXPERIMENTAL
Intervention: BW-GA-weight-gain model
Number of subjects: 367
Study 19221377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency face-to-face lifestyle modification counseling (HF-F2F)
Number of subjects: 376
Study 19221377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency telephone counseling (HF-TEL)
Number of subjects: 376
Study 19221377 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency face-to-face counseling (LF-F2F)
Number of subjects: 376
Study 19221377 — intervention group
Group type: COMPARATOR
Intervention: High-frequency email counseling (HF-EMAIL)
Number of subjects: 376
Study 19221377 — intervention group
Group type: COMPARATOR
Intervention: Self-help (SELF)
Number of subjects: 376
Study 19221377 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 376
Study 16500492 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced 3D dobutamine stress echocardiography
Number of subjects: 78
Study 16500492 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced 2D dobutamine stress echocardiography
Number of subjects: 78
Study 15555700 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term individual psychotherapy
Number of subjects: 60
Study 11099758 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of dexamphetamine sulphate
Number of subjects: 3
Study 11099758 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of dexamphetamine sulphate
Number of subjects: 3
Study 11099758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 9313019 — intervention group
Group type: EXPERIMENTAL
Intervention: High social class
Number of subjects: 2145
Study 9313019 — intervention group
Group type: COMPARATOR
Intervention: Low or middle social class
Number of subjects: 2145
Study 7921303 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin and mineral supplements for 6 years
Number of subjects: 3318
Study 7921303 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of four different vitamin and mineral combinations for 5 1/4 years
Number of subjects: 3318
Study 7921303 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 years
Number of subjects: 3318
Study 7921303 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 1/4 years
Number of subjects: 3318
Study 30928926 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy (GMT)
Number of subjects: 1000
Study 30928926 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational choir singing (RCS)
Number of subjects: 1000
Study 30928926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GMT and RCS
Number of subjects: 1000
Study 30928926 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 1000
Study 30928926 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (GMT, RCS, both)
Number of subjects: 1000
Study 29798206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with 10mg oral ebastine plus 200 μg intranasal mometasone furoate once daily (combined group)
Number of subjects: 82
Study 29798206 — intervention group
Group type: COMPARATOR
Intervention: Double-dose oral ebastine 20 mg once daily (double-dose group)
Number of subjects: 82
Study 27645761 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 44
Study 24462785 — intervention group
Group type: EXPERIMENTAL
Intervention: Juglans regia leaf extract (100mg, two times a day for 3 months)
Number of subjects: 61
Study 24462785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100mg, two times a day for 3 months)
Number of subjects: 61
Study 24462785 — intervention group
Group type: EXPERIMENTAL
Intervention: Juglans regia leaf extract
Number of subjects: 61
Study 24462785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Juglans regia and placebo)
Number of subjects: 61
Study 22561772 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion correction only (n=14)
Number of subjects: 50
Study 22561772 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Relaxant + anti‐depressant drug (n=26)
Number of subjects: 50
Study 22561772 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy + antidepressant drug + muscle relaxant (n=6)
Number of subjects: 50
Study 22561772 — intervention group
Group type: EXPERIMENTAL
Intervention: Appliance + muscle relaxant (n=4)
Number of subjects: 50
Study 19667999 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 64
Study 19667999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin 1700 mg/day and rosiglitazone 4 mg/day
Number of subjects: 64
Study 19667999 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1700 mg/day
Number of subjects: 64
Study 18721168 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII), n = 34
Number of subjects: 72
Study 18721168 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI), n = 38
Number of subjects: 72
Study 18721168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 17135985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine (FLX) and cognitive-behavioral therapy (CBT)
Number of subjects: 439
Study 17135985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439
Study 17135985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 439
Study 17135985 — intervention group
Group type: COMPARATOR
Intervention: Clinical management with pill placebo (PBO)
Number of subjects: 439
Study 17135985 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 439
Study 17135985 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders by CGI-I criteria
Number of subjects: 439
Study 14575277 — intervention group
Group type: EXPERIMENTAL
Intervention: manidipine 20 mg daily
Number of subjects: 101
Study 14575277 — intervention group
Group type: COMPARATOR
Intervention: nifedipine 60 mg daily
Number of subjects: 101
Study 11004652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for T(x) distance
Number of subjects: 3
Study 11004652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for vertebra(apex)
Number of subjects: 3
Study 11004652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for Rz
Number of subjects: 3
Study 11004652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraexaminer reliability for CDA
Number of subjects: 3
Study 11004652 — intervention group
Group type: EXPERIMENTAL
Intervention: Interexaminer reliability among 3 examiners
Number of subjects: 3
Study 8713789 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 x 10(6) U/m2)
Number of subjects: 8
Study 1383574 — intervention group
Group type: EXPERIMENTAL
Intervention: finasteride (10 mg per day)
Number of subjects: 28
Study 1383574 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 3996091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (500 mg intravenous infusion)
Number of subjects: 80
Study 3996091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 3996091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tinidazole
Number of subjects: 80
Study 31291515 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (300 mg, subcutaneously at baseline and at 1 month)
Number of subjects: 106
Study 31291515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously at baseline and at 1 month)
Number of subjects: 106
Study 31291515 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (300 mg)
Number of subjects: 106
Study 31291515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 28702899 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex antioxidant (antiOx)
Number of subjects: 63
Study 28702899 — intervention group
Group type: COMPARATOR
Intervention: One-a-day multivitamin (mV)
Number of subjects: 63
Study 27235953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance stimuli (various physical parameters)
Number of subjects: 97
Study 27235953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance stimuli (motion energy, luminance)
Number of subjects: 97
Study 27235953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance stimuli (roundedness in posture shape)
Number of subjects: 97
Study 27235953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance stimuli (impressive movements)
Number of subjects: 97
Study 27235953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance stimuli (imagery and autobiographical memories)
Number of subjects: 97
Study 27235953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance stimuli (physical parameters)
Number of subjects: 97
Study 24853120 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (1500 mg/day in 3 divided doses)
Number of subjects: 40
Study 24853120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22038086 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based psychological group program (10 sessions over 10 months)
Number of subjects: 337
Study 22038086 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 337
Study 20350836 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1800 pulses; 1 Hz rate; intensity just below active motor threshold)
Number of subjects: 9
Study 20350836 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 9
Study 20350836 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 9
Study 17368094 — intervention group
Group type: COMPARATOR
Intervention: Memantine
Number of subjects: 6
Study 17368094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 15720497 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional discharge model
Number of subjects: 0
Study 12053718 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose therapy
Number of subjects: 13
Study 12053718 — intervention group
Group type: COMPARATOR
Intervention: BCNU containing American Intergroup study
Number of subjects: 13
Study 27093747 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 12
Study 27093747 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 12
Study 27093747 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (15 g)
Number of subjects: 12
Study 7607713 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg losartan + 25 mg hydrochlorothiazide
Number of subjects: 304
Study 7607713 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan + 25 mg hydrochlorothiazide
Number of subjects: 304
Study 7607713 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg losartan + 25 mg hydrochlorothiazide
Number of subjects: 304
Study 7607713 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 25 mg hydrochlorothiazide
Number of subjects: 304
Study 7607713 — intervention group
Group type: EXPERIMENTAL
Intervention: All losartan groups
Number of subjects: 304
Study 7607713 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 304
Study 2218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 10-14 days
Number of subjects: 192
Study 2218421 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 200 mg once daily followed by 100 mg once daily for 10-14 days
Number of subjects: 192
Study 23338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 0
Study 31368998 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational adaptive optics (CAO) using multiple randomized subaperture correlations
Number of subjects: 0
Study 28455250 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent video education about infant soothing (video)
Number of subjects: 352
Study 28455250 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and oral sucrose solution (sucrose)
Number of subjects: 352
Study 28455250 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and sucrose and topical liposomal lidocaine (lidocaine)
Number of subjects: 352
Study 28455250 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (standard care)
Number of subjects: 352
Study 26266386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plus dexmedetomidine (0.02 μg/kg/h sufentanil + 0.05 μg/kg/h dexmedetomidine) (Group D2)
Number of subjects: 90
Study 26266386 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (0.02 μg/kg/h) (Group C)
Number of subjects: 90
Study 26266386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plus dexmedetomidine (0.02 μg/kg/h sufentanil + 0.02 μg/kg/h dexmedetomidine) (Group D1)
Number of subjects: 90
Study 26266386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plus dexmedetomidine (Group D1 and D2)
Number of subjects: 90
Study 24057042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1,250 mg once daily) and Everolimus (5 mg once daily)
Number of subjects: 23
Study 24057042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and Everolimus combination
Number of subjects: 23
Study 21945050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic septoplasty (surgery) in group A (A2)
Number of subjects: 138
Study 21945050 — intervention group
Group type: COMPARATOR
Intervention: Control group A1 (no surgery)
Number of subjects: 138
Study 21945050 — intervention group
Group type: COMPARATOR
Intervention: Control group B1 (no surgery)
Number of subjects: 138
Study 21945050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic septoplasty (surgery) in group B (B2)
Number of subjects: 138
Study 19920721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating cold device
Number of subjects: 30
Study 19920721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant
Number of subjects: 30
Study 19920721 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 30
Study 16702318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 0
Study 16702318 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 0
Study 16702318 — intervention group
Group type: COMPARATOR
Intervention: High habitual fish intake (HFI)
Number of subjects: 0
Study 16702318 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's dietary intake of (n‐3) PUFA
Number of subjects: 0
Study 12716684 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g ALA/d
Number of subjects: 150
Study 12716684 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5 g ALA/d
Number of subjects: 150
Study 12716684 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.77 g EPA+DHA/d
Number of subjects: 150
Study 12716684 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g EPA+DHA/d
Number of subjects: 150
Study 12716684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no additional n-3 PUFAs)
Number of subjects: 150
Study 11036040 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV) plus zidovudine (AZT)
Number of subjects: 597
Study 11036040 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (AZT)
Number of subjects: 597